On December 4, 2023, Dara Grantham Wright, the Executive Vice-President and President, Clinical Diagnostics Group, of Bio-Rad Laboratories, Inc. and a named executive officer of the Company, notified the Company of her plans to resign from the Company to pursue another opportunity, effective at the close of business on January 12, 2024. The Company has initiated a search to fill this position.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
282 USD | +1.69% | +0.78% | -12.66% |
08/05 | UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating | MT |
08/05 | RBC Adjusts Price Target on Bio-Rad Laboratories to $414 From $420 | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.66% | 8.03B | |
-4.84% | 182B | |
+0.56% | 110B | |
-3.35% | 68.11B | |
+2.39% | 50.53B | |
+9.36% | 44.8B | |
+2.92% | 40.7B | |
+24.51% | 32.3B | |
+3.43% | 26.53B | |
+13.39% | 25.02B |
- Stock Market
- Equities
- BIO Stock
- News Bio-Rad Laboratories, Inc.
- Bio-Rad Laboratories, Inc. Announces Resignation of Dara Grantham Wright as Executive Vice-President and President, Effective January 12, 2024